At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 77 enrolled
Drug / intervention
CD388 Injection +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Single-Dose and Repeat Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Mar 17, 2022·Updated Feb 27, 2025
In Brief
A Phase 1 clinical trial evaluating CD388 Injection and Saline placebo for Healthy. Completed, enrolled 77 participants across 1 site.
Detailed Summary
The purpose of this first-in-human study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when administered as a single dose to healthy adult subjects by injection either in the muscle or under the skin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsJanssen Pharmaceuticals
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartMar 2022
First PostedMar 2022
Primary CompletionOct 2023
TodayJul 2026
First PostedMar 17, 2022
Enrollment StartMar 14, 2022
Primary CompletionOct 27, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.3 years ago
Interventions
CD388 Injectioncombination
CD388 liquid for injection
Saline placebodrug
Sterile normal saline for injection